Carvedilol phosphate is a phosphate salt of carvedilol, a non-selective beta-adrenergic blocker with alpha-1 blocking activity. This salt form is developed to improve the physicochemical properties, such as solubility and stability, of the parent drug carvedilol, potentially enhancing its bioavailability and formulation characteristics. Carvedilol phosphate is primarily used as an active pharmaceutical ingredient (API) for the treatment of cardiovascular diseases, specifically hypertension and chronic heart failure. Its mechanism involves blocking both beta-1, beta-2, and alpha-1 adrenergic receptors, leading to vasodilation and reduced cardiac workload. It also finds application in the management of certain neurological conditions, such as essential tremor, due to its beta-blocking properties. The development of carvedilol phosphate represents a pharmaceutical strategy to create improved dosage forms, such as immediate-release or controlled-release tablets, offering potential therapeutic advantages over the free base. As a salt of a well-established drug, its safety profile is closely related to that of carvedilol, with common side effects including dizziness, fatigue, and hypotension.